Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 194,606 | 276,771 | 233,912 | 241,214 | 228,424 |
| Receivables | 720,915 | 780,375 | 752,390 | 642,881 | 617,740 |
| Inventories | 278,544 | 380,259 | 255,809 | 199,146 | 185,695 |
| Other current assets | 105,796 | 83,378 | 107,580 | 97,311 | 72,560 |
| TOTAL | $1,403,071 | $1,608,662 | $1,439,032 | $1,274,095 | $1,201,131 |
| Non-Current Assets | |||||
| PPE Net | 1,604,014 | 1,639,741 | 1,465,655 | 1,291,068 | 1,124,358 |
| Investments And Advances | 218,350 | 243,811 | 311,602 | 201,352 | 0 |
| Intangibles | 3,570,008 | 3,959,096 | 3,805,178 | 3,773,073 | 1,875,262 |
| Other Non-Current Assets | 732,902 | 743,690 | 581,304 | 484,704 | 1,290,080 |
| TOTAL | $6,125,274 | $6,586,338 | $6,163,739 | $5,750,197 | $4,289,700 |
| Total Assets | $7,528,345 | $8,195,001 | $7,602,770 | $7,024,292 | $5,490,831 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 50,214 |
| Accounts payable and accrued liabilities | 140,337 | 168,937 | 205,915 | 198,130 | 122,475 |
| Accrued Expenses | 411,428 | 441,115 | 416,836 | 474,916 | 356,643 |
| Other current liabilities | 194,014 | 203,210 | 204,575 | 140,436 | 102,477 |
| TOTAL | $994,101 | $1,055,082 | $1,091,585 | $1,033,185 | $839,751 |
| Non-Current Liabilities | |||||
| Long Term Debt | 2,240,205 | 2,647,147 | 2,707,531 | 2,663,564 | 1,929,571 |
| Deferred Revenues | 248,322 | 241,820 | 264,259 | 219,703 | 207,942 |
| Other Non-Current Liabilities | 717,039 | 693,401 | 600,612 | 540,986 | 385,307 |
| TOTAL | $3,067,292 | $3,537,643 | $3,530,107 | $3,452,125 | $2,532,911 |
| Total Liabilities | $4,061,393 | $4,592,725 | $4,621,692 | $4,485,310 | $3,372,662 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 51,142 | 51,350 | 50,986 | 50,486 | 49,776 |
| Common Shares | 511 | 513 | 509 | 505 | 498 |
| Retained earnings | 1,812,100 | 1,887,218 | 1,432,901 | 980,751 | 625,414 |
| Other shareholders' equity | -311,896 | -191,033 | -257,272 | -160,578 | -135,307 |
| TOTAL | $3,466,952 | $3,602,276 | $2,981,078 | $2,538,982 | $2,118,169 |
| Total Liabilities And Equity | $7,528,345 | $8,195,001 | $7,602,770 | $7,024,292 | $5,490,831 |